Stephens Investment Management Group LLC Decreases Holdings in Repligen Co. (NASDAQ:RGEN)

Stephens Investment Management Group LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN) by 13.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 739,116 shares of the biotechnology company’s stock after selling 118,062 shares during the quarter. Repligen accounts for about 1.2% of Stephens Investment Management Group LLC’s holdings, making the stock its 17th biggest position. Stephens Investment Management Group LLC owned about 1.57% of Repligen worth $63,527,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of RGEN. Huntington National Bank acquired a new position in shares of Repligen during the 1st quarter worth approximately $25,000. Royce & Associates LP raised its position in shares of Repligen by 40.6% during the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 145 shares during the last quarter. Mascoma Wealth Management LLC acquired a new position in shares of Repligen during the 1st quarter worth approximately $41,000. Private Capital Group LLC raised its position in shares of Repligen by 675.3% during the 1st quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares during the last quarter. Finally, South Dakota Investment Council acquired a new position in shares of Repligen during the 1st quarter worth approximately $83,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

In other news, Director Glenn L. Md Cooper sold 5,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the sale, the director now directly owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 1,295 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $77.35, for a total transaction of $100,168.25. Following the sale, the director now directly owns 118,329 shares of the company’s stock, valued at $9,152,748.15. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.

RGEN has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Repligen in a research report on Monday. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Craig Hallum lifted their price objective on Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $97.50.

RGEN traded up $0.03 during trading on Thursday, hitting $88.84. The company’s stock had a trading volume of 7,079 shares, compared to its average volume of 776,547. The business has a 50 day simple moving average of $88.42. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.88 and a current ratio of 2.25. The stock has a market cap of $4.64 billion, a PE ratio of 121.46, a PEG ratio of 5.28 and a beta of 1.08. Repligen Co. has a twelve month low of $48.26 and a twelve month high of $99.25.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.06. The company had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a return on equity of 6.92% and a net margin of 11.42%. Repligen’s revenue was up 48.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.14 EPS. As a group, research analysts expect that Repligen Co. will post 0.97 EPS for the current year.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.